MedicaidPrior AuthMedium impact
Zycubo® (copper histidinate) Powder for Injection (New)
Humana·KY, SC, VA · Pediatrics, Pharmacy·Medicaid
Effective date
Feb 25, 2026
We identified it
Jun 25, 2026
Summary
Humana has established a new prior authorization policy for Zycubo® (copper histidinate) Powder for Injection, effective February 25, 2026, covering treatment of genetically-confirmed Menkes disease in pediatric patients up to age 17 across Kentucky, South Carolina, and Virginia Medicaid programs. All claims require prior authorization with verification of ATP7A gene mutation confirmation and age eligibility before dispensing.
Action Required
By February 25, 2026: Billing team must implement prior authorization requirements for Zycubo claims in Kentucky, South Carolina, and Virginia Medicaid programs. Establish workflow to: (1) Verify member age ≤17 years at time of request, (2) Confirm provider attestation of ATP7A gene mutation genetic confirmation in member record, (3) Submit prior authorization through Humana PAL (www.humana.com/PAL) before dispensing each fill, (4) Update pharmacy billing system to flag Zycubo as requiring prior auth for affected state Medicaid plans. Providers must document genetic confirmation of Menkes disease diagnosis and member age on all requests. Failure to obtain prior authorization will result in claim denials. Train pharmacy staff and notify prescribing providers of new requirements immediately.